Answers are grounded in this paper and cite their sources.
Post-marketing surveillance confirms safety and effectiveness of dolutegravir treatments in HIV-positive individuals, suggesting ongoing therapeutic value.
This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Sebata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: